EMA Rejects 76% Of Requests To Label Info In Clinical Reports As Commercially Confidential

Most of the proposals by companies to redact commercially confidential information in their clinical study reports under the European Medicines Agency’s policy on proactive publication of clinical trial data have been rejected. Meanwhile, the agency is planning to make improvements to the policy this year.

Protection
In Many Cases, Information Proposed As CCI Was Already Publicly Available • Source: Shutterstock

More from Clinical Trials

More from R&D